Galapagos' evolution inflection
Filgotinib data key to Galapagos' evolution to a pure play product developer
Data next month for filgotinib will be the first near-term opportunity for Galapagos N.V. to show it can complete its shift from hybrid discovery/service company into a product-focused play.
The Janus kinase-1 (JAK-1) inhibitor will produce data this year from a series of Phase II trials in RA and Crohn's disease. Good results would trigger AbbVie Inc.'s option to the program, bringing in cash to support the unpartnered clinical and preclinical programs in Galapagos' pipeline.
Even before advancing its first compound into the clinic in 2009, Galapagos billed itself as a drug discovery service company with its own in-house programs. But CEO Onno van de Stolpe said the hybrid business model wasn't a long-term aim, but rather a bridge to bring in revenue at lower risk while the company built a pipeline.
"When we started, the road to a meaningful development pipeline was so long that we had to do something else to keep investors interested. The service divisions did that, and we could use the services for the progression of our own programs, but